STAT
Biotech innovations dominate the life science news cycle — think CRISPR for gene editing or CAR-T for cancer immunotherapy. Medical technologies, encompassing the broad swath of devices and interventional technologies, diagnostics, imaging, and digital medicine, tend to make their marks out of the limelight, yet have an enormous impact on public health and offer significant investment opportunities.
Read MoreFor decades, the time-consuming and vastly expensive nature of drug discovery has been a significant pain point for pharmaceutical and biotech companies, who continually seek new technologies to improve the process.
Read MoreAs healthcare evolves to become more patient-centric, the FDA has expressed increasing interest in the use of patient-reported outcomes (PROs) as endpoints in clinical trials. A PRO is any report, directly from the patient, that provides information on the status of the patient’s health, disease burden, medication usage, and other experiences.
Read MoreOn Friday, June 29 Amazon announced that it would be acquiring its first online pharmacy retailer, PillPack for $1 billion in cash. With around $100 million in revenue last year, the acquisition price implies a 9x – 10x revenue multiple for the Company.
Read MoreThe United States is a leader in the life sciences industry, but through deep regulatory reform, ambitious international strategy, and a surge of financings, China has recently enjoyed a biotechnology boom that in time could challenge this competitive edge.
Read MoreThe Massachusetts Biotechnology Council (MassBio®), launched an Academic-Industry Roundtable Series to create pathways for better collaboration and progress innovative technologies in the life sciences.
Read MoreEvery major life science conference we attend now has a digital health track, as this broad and evolving field and everything it encompasses continues to grab industry attention.
Read MoreWith the wrap up of the annual meeting of The American Society of Clinical Oncology (ASCO), we’re left with much to consider around new treatments in development that could deliver improved life expectancy and offer continued hope to millions of people.
Read MoreEuropean life science companies face a relative lack of capital compared to US companies. This gap engenders differing styles of investment and exit opportunities in Europe that can have meaningful implications for business plans and execution differences between the two continents.
Read MoreThe underlying premise at Back Bay Life Science Advisors is that any accurate asset or company valuation must be derived from a fundamental understanding of the scientific, clinical, and commercial aspects of the financial models in use.
Read More